Detalhe da pesquisa
1.
Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Eur J Pediatr
; 183(5): 2141-2153, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38366267
2.
A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years.
J Pediatr X
; 5: 100055, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-37332660